Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia.

Chinese medical journal - 20 Oct 2016

Sun Jie, Hu Juan, Huang Yan, Ying Shuang-Wei, Han Xiao-Yan, Zheng Yan-Long, Huang He

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to fms-Like Tyrosine Kinase 3
Share to Leukemia, Myeloid, Acute
Share to Mutation
Share to Niacinamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenylurea Compounds

Share to Sorafenib

Share to Tandem Repeat Sequences

Source

Open in PubMed Open full text

Identifiers

PMID: 27748350
DOI: 10.4103/0366-6999.191831
PMCID: PMC5072270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia.PMID 27748350Read ↗

[Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation].Semantic proximity Read ↗

Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia.Semantic proximity Read ↗

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.Semantic proximity Read ↗

Non-internal tandem duplication (ITD), non-tyrosine kinase domain (TKD) FLT3 mutations in myeloid malignancies: A brief report of 10 patients.Semantic proximity Read ↗

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.Semantic proximity Read ↗

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.Semantic proximity Read ↗

[Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].Semantic proximity Read ↗

Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.Semantic proximity Read ↗

Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.Semantic proximity Read ↗

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Semantic proximity Read ↗

Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports.Semantic proximity Read ↗

Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.